NEW YORK, October 31, 2016 /PRNewswire/ --
Stock-Callers.com has initiated coverage on four Generic Drugs companies,namely: Evoke Pharma Inc. (NASDAQ: EVOK), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Galectin Therapeutics Inc. (NASDAQ: GALT). These stocks belong to the Healthcare
Solana Beach, California headquartered Evoke Pharma Inc.'s stock dropped 3.93%, finishing last Friday's session at $1.71 with a total trading volume of 146,014 shares. Shares of the Company, which primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases, shares are trading below their 50-day moving average by 14.23%. The stock has a Relative Strength Index (RSI) of 31.02. Your complete research report on EVOK can be retrieved for free at:
On Friday, shares in Coral Gables, Florida-based Catalyst Pharmaceuticals Inc. ended the session 6.48% lower at $0.98. The stock recorded a trading volume of 964,759 shares. The Company's shares have gained 29.69% in the previous three months. The stock is trading below its 200-day moving average by 6.86%. Moreover, shares of Catalyst Pharmaceuticals, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have an RSI of 35.95.
As per notes filed with the SEC on October 3rd, 2016, Catalyst Pharmaceuticals received a notice from The NASDAQ Stock Market on September 30th, 2016, confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. On June 9th, 2016, NASDAQ notified the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. The Rule requires that listed securities maintain a minimum bid price of $1.00 per share.
On October 5th, 2016, research firm Piper Jaffray upgraded the Company's stock rating from 'Neutral' to 'Overweight'. CPRX free report is just a click away at:
San Diego, California headquartered Neurocrine Biosciences Inc.'s stock declined 0.89%, to close the day at $44.38 with a total trading volume of 536,530 shares. Shares of the Company, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US, are trading 1.85% below their 200-day moving average. The stock has an RSI of 41.33.
On October 18th, 2016, research firm Needham initiated a 'Buy' rating on the Company's stock, issuing a target price of $62 per share.
On October 19th, 2016, AbbVie in cooperation with Neurocrine Biosciences announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. AbbVie plans to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) for endometriosis in 2017. Sign up for your complimentary research report on NBIX at:
Shares in Norcross, Georgia-based Galectin Therapeutics Inc. recorded a trading volume of 254,297 shares. The stock ended Friday's session at $0.75, down 2.60%. The Company's shares are trading below their 200-day moving average by 49.08%. Furthermore, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease and cancer, have an RSI of 27.92.
On September 27th, 2016, Galectin Therapeutics announced that top-line results from NASH-FX, its Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of GR-MD-02 in 30 nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis, did not meet its primary biomarker endpoint as measured by LiverMultiScan. The trial also did not meet secondary endpoints that measure liver stiffness as a surrogate for fibrosis, with FibroScan® and magnetic resonance elastography (MRE). Galectin simultaneously announced that the principal focus of its research efforts - its larger scale, one-year, multi-site trial in patients with NASH cirrhosis (NASH-CX) - has completed enrollment one month early with 162 total subjects, allowing for reporting of top-line results in December 2017.
On October 3rd, 2016, research firm FBR & Co. downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. The research firm also revised downwards its previous target price from $12 a share to $2 a share. Register for free on Stock-Callers.com and download the latest research report on GALT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Adult immunization is needed for adults whose mandatory childhood vaccines were either missed out ...
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast ...View All